Cadila Healthcare is currently trading at Rs. 270.50, up by 1.75 points or 0.65% from its previous closing of Rs. 268.75 on the BSE.
The scrip opened at Rs. 270.00 and has touched a high and low of Rs. 271.65 and Rs. 265.95 respectively. So far 14614 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 352.30 on 01-Apr-2019 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 282.50 and Rs. 265.95 respectively. The current market cap of the company is Rs. 27625.69 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.20% and 7.80% respectively.
Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use, (US RLD - Canasa) 1000 mg. The drug is used to treat ulcerative proctitis, a type of bowel disease. It is an amino salicylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.